Your data on MRCVSonline
The nature of the services provided by Vision Media means that we might obtain certain information about you.
Please read our Data Protection and Privacy Policy for details.

In addition, (with your consent) some parts of our website may store a 'cookie' in your browser for the purposes of
functionality or performance monitoring.
Click here to manage your settings.
If you would like to forward this story on to a friend, simply fill in the form below and click send.

Your friend's email:
Your email:
Your name:
 
 
Send Cancel

Promising new live vaccine for equine influenza
The vaccine was created using reverse genetics, which means it can be updated to protect against emerging strains.
Scientists say progress is important for human and animal health

A new ‘live attenuated’ vaccine against equine influenza is showing promise, an initial trial suggests.

According to a paper published in the journal Virology, a single spray of the vaccine protected mice and horses against the H3N8 equine influenza virus, which is currently circulating.

Vaccinated horses reportedly showed none of the ‘tell-tale’ signs of influenza - which include nasal discharge, coughing and wheezing - after being exposed to a natural virus. In addition, scientists said no negative side effects were seen.

However, the study was small and involved only six horses, so plans are underway to conduct a larger study.

Given as a spray through the nose, the vaccine works by replicating and generating an immune response in the nose, where the virus first enters the body. Researchers from the University of Rochester Medical Center said the idea is to stop the virus taking hold in the horse’s respiratory tract.

The vaccine was created using a genetic engineering technique called reverse genetics, which offers a major advantage as it can be updated quickly and easily to protect against emerging strains. Traditional vaccines, on the other hand, take months to produce and do not allow the same flexibility.

Equine influenza is currently circulating in North America and Europe and is highly contagious, yet there has not been an updated vaccine for 25 years.

Associate professor Luis Martinez-Sobrido, said a new vaccine is not only important for animal health, but for humans too.

Animals such as horses, pigs and dogs can be infected with multiple influenza viruses and have the potential to act as ‘mixing vessels’, creating new strains that could infect people. While this has not yet occurred, it is possible, and these strains would be particularly dangerous as humans would have no pre-existing immunity.

Become a member or log in to add this story to your CPD history

RCVS Knowledge appoints Veterinary Evidence editor-in-chief

News Story 1
 RCVS Knowledge has welcomed Professor Peter Cockcroft as editor-in-chief for Veterinary Evidence.

A world-renowned expert in evidence-based veterinary medicine, Prof Cockcroft will lead the strategic development and editorial quality of the open-access journal. He was previously in the role from 2017-2020.

Katie Mantell, CEO of RCVS Knowledge, said: "We are excited about the extensive knowledge of evidence-based veterinary medicine and clinical veterinary research that Peter brings, and we look forward to working with him over this next phase of the journal's development." 

Click here for more...
News Shorts
Defra to host bluetongue webinar for vets

The Department for Environment, Food and Rural Affairs (Defra) will be hosting a webinar for veterinary professional on bluetongue on Thursday, 25 April 2024.

Topics covered will include the transmission cycle, pathology and pathogenesis, clinical signs (including signs seen in recent BTV-3 cases in the Netherlands), and control and prevention.

The session, which will take place from 6pm to 7.30pm, is part of Defra's 'Plan, Prevent and Protect' webinar series, which are hosted by policy officials, epidemiologists and veterinary professionals from Defra and the Animal and Plant Health Agency. The bluetongue session will also feature insights from experts from The Pirbright Institute.

Those attending will have the opportunity to ask questions. Places on the webinar can be booked online.